New Hepatitis B Drug Shows 20% Functional Cure Rate

Imagine taking a pill every single day for the rest of your life just to keep a virus at bay. That's been the reality for millions of hepatitis B patients, but a new treatment is changing the game.

Bepirovirsen, developed by GSK, has shown remarkable results in phase 3 clinical trials published in The New England Journal of Medicine in May 2026. Around 20% of patients achieved what doctors call a "functional cure," meaning the virus became undetectable and they could potentially stop treatment.

That might not sound like a huge number, but it's groundbreaking. Current hepatitis B medications only achieve functional cure in about 1% of patients per year, and most people stay on daily pills for decades or life.

Dr. Norah Terrault, chief of gastroenterology at USC's Keck School of Medicine and a co-investigator in the study, calls this "an amazing feat." Hepatitis B affects hundreds of millions of people worldwide and can lead to cirrhosis and liver cancer if left uncontrolled.

The current standard treatments work well at suppressing the virus, but they don't eliminate it. Patients take entecavir or tenofovir daily to keep the virus in check and prevent liver damage. It's effective but requires constant vigilance.

Bepirovirsen works differently. Instead of just suppressing the virus, it helps some patients clear hepatitis B surface antigen from their blood, the key marker that signals functional cure. When that happens, patients may be able to stop treatment while staying healthy.

Why This Inspires

This isn't just about avoiding a daily pill. It's about giving people their lives back. The mental burden of managing a chronic condition every single day takes a real toll.

For patients in countries with limited healthcare access, where consistent medication supply can be challenging, a functional cure could be truly life-changing. It means freedom from worrying about medication costs, side effects, or forgetting a dose.

The research shows we're entering a new era of hepatitis B treatment, where the goal isn't just management but actual cure. Scientists are finally cracking the code on a virus that's plagued humanity for generations.

One in five patients finding functional cure today could become two in five tomorrow as researchers refine these approaches. Each breakthrough builds on the last, bringing us closer to the day when hepatitis B becomes a curable disease rather than a lifelong condition.

For the estimated 296 million people living with chronic hepatitis B worldwide, hope just got a lot more concrete.